![David Rabuka](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Rabuka
Amministratore Delegato presso Acrigen Biosciences, Inc.
Profilo
David Rabuka was the founder of Redwood Bioscience, Inc. (founded in 2008) and Acrigen Biosciences, Inc. (founded in 2019), where he held the titles of Chief Scientific Officer and President & Chief Executive Officer, respectively.
He also worked as a Staff Scientist at Optimer Pharmaceuticals LLC.
Dr. Rabuka received his graduate degree from the University of Alberta, his undergraduate degree from the University of Saskatchewan, and his doctorate from the University of California, Berkeley.
Posizioni attive di David Rabuka
Società | Posizione | Inizio |
---|---|---|
Acrigen Biosciences, Inc.
![]() Acrigen Biosciences, Inc. BiotechnologyHealth Technology Acrigen Biosciences, Inc. operates as a early-stage life science gene editing company. The company was founded by Joseph Bondy-Denomy in 2019 and is headquartered in Kensington, CA. | Amministratore Delegato | 01/01/2019 |
Precedenti posizioni note di David Rabuka
Società | Posizione | Fine |
---|---|---|
Optimer Pharmaceuticals LLC
![]() Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Corporate Officer/Principal | - |
Redwood Bioscience, Inc.
![]() Redwood Bioscience, Inc. BiotechnologyHealth Technology Redwood Bioscience Inc. develops precision protein-chemical engineering technology to produce the next-generation of antibody-drug conjugates and other semi-synthetic biotherapeutics. It employs natural post translational modifications found in human cells to site specifically create one or more aldehyde tags on protein molecules, including monoclonal antibodies. The firm's platform is enabled with precision chemistries, payload positioning and defined stoichiometry of payload protein ratios. The company was founded by Carolyn R. Bertozzi, Mike Blank and David Rabuka in 2008 and is headquartered in Emeryville, CA. | Fondatore | - |
Formazione di David Rabuka
University of California, Berkeley | Doctorate Degree |
University of Alberta | Graduate Degree |
University of Saskatchewan | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Redwood Bioscience, Inc.
![]() Redwood Bioscience, Inc. BiotechnologyHealth Technology Redwood Bioscience Inc. develops precision protein-chemical engineering technology to produce the next-generation of antibody-drug conjugates and other semi-synthetic biotherapeutics. It employs natural post translational modifications found in human cells to site specifically create one or more aldehyde tags on protein molecules, including monoclonal antibodies. The firm's platform is enabled with precision chemistries, payload positioning and defined stoichiometry of payload protein ratios. The company was founded by Carolyn R. Bertozzi, Mike Blank and David Rabuka in 2008 and is headquartered in Emeryville, CA. | Health Technology |
Optimer Pharmaceuticals LLC
![]() Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Health Technology |
Acrigen Biosciences, Inc.
![]() Acrigen Biosciences, Inc. BiotechnologyHealth Technology Acrigen Biosciences, Inc. operates as a early-stage life science gene editing company. The company was founded by Joseph Bondy-Denomy in 2019 and is headquartered in Kensington, CA. | Health Technology |
- Borsa valori
- Insiders
- David Rabuka